A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Trial Profile

A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs VL 2397 (Primary)
  • Indications Mycoses
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 02 May 2017 Results from this trial will be presented at the ASM Microbe 2017 conference, according to a Vical media release.
    • 09 Mar 2017 Status changed from recruiting to completed, according to a Vical media release.
    • 09 Mar 2017 According to a Vical media release, full data will be presented at an upcoming scientific conference in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top